Carolyn Pelletier

Scientist at Carbon Biosciences

Carolyn Pelletier has worked as a Scientist at Carbon Biosciences since 2022, a Scientist at Paros Bio since 2019, a Principal Associate Scientist at Generation Bio since 2018, a Senior Associate I and Associate Scientist III at Biogen from 2009 to 2018, and an Associate Scientist II at Biogen from 2000 to 2009. During their time at Biogen, they performed assays in support of routine testing, validation studies, and investigations, prepared and tested molecular biology reagents, provided technical leadership with assay method development, improvement, validation and investigations, designed and executed Q-PCR assays for the detection of AAV-2 and SV-40, performed investigational cell-based experiments using MycoSEQ for Mycoplasma detection, executed in vitro adventitious virus testing by performing cytopathic effect and hemadsorption observations, and performed isoenzyme analysis for Biogen manufactured clinical and commercial cell banks.

Carolyn Pelletier obtained their Bachelor of Science degree in Microbiology, General from the University of New Hampshire between 1993 and 1997. Carolyn then went on to earn their Master's Degree in Bioscience Administration from Worcester Polytechnic Institute between 2015 and 2017.

Location

Salem, United States

Links


Org chart

No direct reports

Teams


Offices


Carbon Biosciences

1 followers

Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.


Employees

11-50

Links